The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
Preclinical and clinical research shows that the cannabinoid brain receptor type 1 (CB1) modulates alcohol- and nicotine-related behaviors. Throughout the nicotine-induced relapse to alcohol, the rats were pre-treated for 10 days with the CB1 cannabinoid receptor antagonist rimonabant (0, 0.03, 0.3...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Elsevier
2007-02-01
|
| Edice: | Neurobiology of Disease |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S0969996106002385 |